Trial
NCT02407223
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Nonradiographic Axial Spondylitis, Ankylosing
Intervention
Group 1: Placebo
Why stopped
This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-13